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Two major clinical challenges are encountered in the management of patients suffering
from depression whether they are treatment resistant or not. First, there is the challenge of obtaining complete symptomatic remission in the acute treatment phase. With
more failed treatments, the probability of remission in the acute phase decreases.1,2
The second challenge focuses on the maintenance of the optimal symptomatic benefit
once achieved in the acute treatment phase, that is, the prevention of relapse (a return
of the current episode) or recurrence (onset of a new episode).3,4 The Sequenced
Treatment Alternatives to Achieve Remission in Depression (STAR-D) trial found
that relapse rates were higher in participants whose depression had failed to benefit
adequately from a large number of prior acute phase treatment trials (ie, they were rated
as having a greater level of “treatment resistance”).1 These two challenges – obtaining
remission or at least a response, and then sustaining that benefit over time – are central
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Objective: To compare the durations of response achieved with adjunctive vagus nerve
stimulation (VNS + TAU) vs treatment as usual (TAU) alone in treatment-resistant depression
(TRD) over a 5-year period in the TRD registry.
Materials and methods: Data from 271 participants on TAU and 328 participants on VNS +
TAU were analyzed. Response was defined as 50% decrease in baseline Montgomery–Åsberg
Depression Rating Scale (MADRS) score at postbaseline visit and was considered retained until
the decrease was 40%. MADRS was obtained quarterly in year 1 and biannually thereafter.
Time-to-events were estimated using Kaplan–Meier method and compared using log-rank
test. HR was estimated using Cox proportion hazard model.
Results: In the VNS + TAU arm, 62.5% (205/328) of participants had a first response over
5 years compared with 39.9% (108/271) in TAU. The time to first response was significantly
shorter for VNS + TAU than for TAU (P0.01). For responders in the first year, median time to
relapse from first response was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU vs 7.3 months
(Q1=3.1, Q3=17.6) for TAU (P0.01). HR=0.6 (95% CI: 0.4, 0.9) revealed a significantly
lower chance for relapse in VNS + TAU. Probability of retaining first response for a year was
0.39 (0.27, 0.51) for TAU and 0.47 (0.38, 0.56) for VNS + TAU. Timing of the onset of the
response did not impact the durability of the response.
Conclusion: VNS therapy added to TAU in severe TRD leads to rapid onset and higher
likelihood of response, and a greater durability of the response as compared to TAU alone.
Keywords: depressive disorder, treatment-resistant depression, vagus nerve stimulation,
longitudinal study, durability of response

Dovepress

Neuropsychiatric Disease and Treatment downloaded from https://www.dovepress.com/ by 128.252.174.220 on 11-Jul-2019
For personal use only.

Kumar et al

challenges in long-term depression management. This issue
is even more pronounced in patients with higher levels of
treatment resistance.
Vagus nerve stimulation (VNS) therapy entails the use
of an implantable device in persons with severe treatmentresistant depression (TRD).5,6 VNS is used as an adjunct
or “add-on” treatment to ongoing medication treatment
(typically antidepressant or mood stabilizing agents or other
“augmenting” agents), in persons with TRD. The standard
threshold for defining TRD in the VNS trials is failure of four
adequate prior antidepressant treatments, although there is
currently not a complete consensus on the required number
of medication failures.7 Several reports have found either an
earlier or more frequent benefit (in both response or remission
rates) with VNS when added to treatment as usual (TAU)
as compared to TAU alone.5,6,8,9 However, the appearance of
symptom benefit is not realized for all participants within the
first 3 months of initiating VNS.5,6,8
Most participants who responded during the pilot and
pivotal VNS TRD studies showed durable clinical benefit.8,10–12
For early responders, 63%–72% showed substantial clinical benefit at 12 months, and these rates were 61%–77% at
24 months. Likewise, 65%–79% of late responders showed
substantial clinical benefit at 24 months.13 Berry et al found
that for VNS + TAU, among participants who achieved
response at 24 weeks as per the Montgomery–Åsberg
Depression Rating Scale (MADRS), 153 (153/217=71%)
had a sustained response at 48 weeks.9,14 Additionally, of
the 104 participants in the VNS + TAU group evaluated at
96 weeks, 70 (70/104=67%) had a sustained MADRS response.
None of the present publications have examined the
long-term durability (up to 4 years) of the VNS-associated
antidepressant responses and how a participant’s response
is affected by the timing of the onset of the response (ie,
do “early” responders stay well longer/shorter than “late
responders”). Also, if participants lose their first response,
what is the chance of achieving another response and how
durable are those responses? We take advantage of a large,
nonrandomized comparison between participants receiving
treatment as usual (TAU) plus VNS as compared to those
receiving TAU alone to answer these questions.6

Aims of the study
We aimed to determine if duration of TRD first response was
more sustained in patients receiving VNS + TAU vs TAU
alone. We also aimed to determine if there is a correlation
between the time at which the first response occurs and the
durability of the response in the VNS + TAU treatment group.
A third exploratory questions was also addressed: In those
458
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TRD patients who respond, and then subsequently relapse,
do the two treatments groups differ in the likelihood of a
second response, time to second response, or durability of
the second response?

Materials and methods
Study population
Participants were part of a Food and Drug Administrationrequired registry of TRD patients followed for 5 years.
The eligibility criteria for the TRD registry are detailed
elsewhere.6,15 Briefly, participants had to be 18 years of age
or older and experiencing a major depressive episode (MDE)
of 2 years or longer in duration (either unipolar or bipolar
depression) or have a history of at least three MDEs including the current depressive episode and a life-time history of
inadequate response to four or more adequate antidepressant
treatments (dosage per Physicians’ Desk Reference labeling
for a minimum of 4 weeks), which could include electroconvulsive therapy (ECT). Participants could not have a history
of psychotic disorder or rapid-cycling bipolar disorder, or
psychotic features in the present MDE (ClinicalTrials.gov
Identifier: NCT00320372).

Study treatment
Before enrollment into the TRD registry, participants (except
for VNS participants who were in the previously reported
flexible dose study and were rolled over into the TRD registry
study; note that these participants were excluded from the
analysis in this article) were allowed to select the treatment
arm of their choice.5 Some participants could be assigned to
receive the alternate treatment by the site for various reasons,
including availability of surgical implantation at a site, number of allocated slots for implantation, or failure to qualify
for insurance reimbursement for VNS therapy implantation.
Device implantation surgery and related medical care were
covered either by a participant’s insurance policy or from
personal funds.
Participants in the VNS + TAU arm underwent implantation during visit 2 (baseline). Postbaseline follow-up visits
for all participants were conducted at 3, 6, 9, 12, 18, 24,
30, 36, 42, 48, 54, and 60 months. Data were collected on
medical status, adjustment of mood disorder therapy (as
needed in the judgment of the clinician), concomitant treatments (with no restrictions on concomitant treatments in
this observational registry), and assessment of depressive
symptom severity (MADRS, administered by offsite blinded
central raters), as well as, the self-rated Quick Inventory of
Depressive Symptomatology-Self Report and the Clinical
Global Impression scale.16–18
Neuropsychiatric Disease and Treatment 2019:15
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Statistical analysis

Of the 494 participants in the VNS + TAU arm reported in
Aaronson et al, 159 participants who had “crossed over”
from VNS treatment in the previously reported flexible dose
study were excluded, as most of these subjects had only
1 year of consistent follow-up data and our study aimed to
understand long-term retention of the response.5,6 In addition, the analysis excluded participants who had a baseline
MADRS score of 10 as it indicated that they were already
remitted from their MDE prior to initiation of treatment; this
excluded n=2 from VNS + TAU and n=5 from TAU alone.19
After the above exclusions and then only including the participants in the intention-to-treat population yielded a total of
328 participants in VNS + TAU group and 271 participants
in TAU group. Note that participants who were crossed over
to another arm during the study were censored at the last visit
before crossover.

Analyses
A time-to-event analysis was conducted for the data as
follows:
• Time to first response was defined as the time from
baseline to the first visit with reduction in MADRS score
of 50% compared to baseline. Note that similar analysis
was done in Aaronson et al.6 However, since our sample is
different, we repeated the analysis to understand whether
trend observed in Aaronson et al is maintained in this
sample.6
• Duration of first response as per MADRS was defined as
the time from first response to the first visit when reduction in MADRS score was 40% compared to baseline.
Similar to Sackeim et al, the criterion for maintenance
of response at the follow-up time points was reduced to
an improvement of at least 40% relative to baseline to
avoid characterizing a minor decrease (eg, from 51% to
49%) as loss of benefit.13 A MADRS score drop of 40%
constituted a clinically meaningful loss of treatment
response, hereafter called “relapse”. Note that only participants who achieved first response within the first year
of starting treatment in the registry were included in this
analysis. These participants could have potentially been
followed-up for 4 years and hence provided a reasonable
sample to assess the long-term durability of first response.
• Time to second response was the time from the first
relapse to the subsequent visit when reduction in MADRS
score was 50% compared to baseline. This analysis was
conducted only for those participants who responded
within the first year and had relapsed after their initial
response.
Neuropsychiatric Disease and Treatment 2019:15

Kumar et al

• Duration of second response was defined as the time from
a second response to a visit when reduction in MADRS
score was 40% compared to baseline. Only first year
responders who relapsed from their first response and
had a second response were included in this analysis.
For all the above data, a probability of time to event was
estimated using Kaplan–Meier (KM) method. KM plots
along with the number of participants at risk at periodic time
points are provided. KM probability estimates for the time to
event with 95% CI at month 3, 6, 9, and 12 are provided. Time
to event curves for the two treatment arms were compared
using log-rank test. A Cox proportion hazards model was
used to estimate the HR (and 95% CI) of the instantaneous
chance of a participant having an event in the VNS + TAU
arm compared to the TAU arm, at any given time during
follow-up.
We evaluated the impact of the timing when the first
response occurred (eg, at 3-, 6-, 9-, or 12-month visits) on
the durability of first response for the VNS + TAU arm.
A KM plot for the time to relapse from the first response
(that occurred in first year) is provided by visit when first
response occurred.

Missing data imputation
We imputed one or two consecutive missing data with the
average of the two adjacent nonmissing data. No imputation was done for three or more consecutive missing data.
After imputation, participants were censored at the last
visit with nonmissing data for all the analysis. Thus, we
had total 2,343 visits with data for TAU participants and
2,991 visits with data for VNS + TAU participants in the
censored data set. Imputation for a single missed data point
in the censored data set was done for 146 visits (146/2,343,
ie, 6.2% of all available data) for TAU participants and for
199 visits (199/2,991, ie, 6.7% of all available data) for
VNS + TAU participants. Imputation for two consecutive
missing data points was done for 82 visits (82/2,343, ie,
3.5% of all available data) for TAU participants and for
106 visits (106/2,991, ie, 3.5% of all available data) for
VNS + TAU participants. Overall there were 228 imputed
data (228/2,343, ie, 9.7% of all available data) in TAU arm
and 305 imputed data (305/2,991, ie, 10.2% of all available
data) in VNS + TAU arm.
The imputation method maintains the pattern of response
status regardless of what threshold is used to define a new
response or maintenance of a response. That is, if a patient
has a response at the adjacent visits then the imputation will
give a response at the missed visit. Similarly, if a patient had
no response at the adjacent visits, then the imputation will
submit your manuscript | www.dovepress.com
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data in VNS + TAU arm. Similarly, when response is defined
as reduction of MADRS score of 40%, the censored data
set provided a regular response pattern around one missing
data 67.1% for TAU and 55.3% for VNS + TAU, and around
two consecutive missing data 85.4% for TAU and 81.1% for
VNS + TAU. Thus, prolongation of the response maintenance
could have occurred only for 3.49% of the censored data in
VNS + TAU arm and 2.56% of the censored data in the TAU
arm. Given the small percentage of data that could have an
altered response pattern due to imputation and noting that
not all alterations in the response pattern are favorable, we
conclude that the imputation method would work reasonably
well for this data set.

give a no-response at the missed visit. Only when responses
are different at the adjacent visits then an imputed response
at a missed visit could thus have prolonged a response maintenance (if pattern is [response, missed visits, no-response])
or could have given an earlier response (if pattern is [noresponse, missed visits, response]). Otherwise imputation
favors only the treatment arm that has more missing data
with adjacent responses, which is indeed desirable.
We provide additional summary below about the
imputed censored data set to show that imputation could
not have altered the result substantially in favor of any of
the treatment arms unless a treatment arm has more missing data with adjacent responses. When response is defined
as reduction of MADRS score of 50%, the censored data
set has a regular response pattern, ie, either response or noresponse at both the adjacent visits around the one missing
data 74.7% for TAU and 62.3% for VNS + TAU, and around
two consecutive missing data 90.2% for TAU and 86.8% for
VNS + TAU. Thus, occurrence of first or second response
could have been altered due to imputation, only for 1.91%
of the censored data for TAU arm and 2.97% of censored

Results
Sample demographics and disease
characteristics
The analysis population included 328 participants in the
VNS + TAU arm and 271 participants in the TAU arm. Baseline demographic characteristics and clinical information for
the analysis population are provided in Table 1.

Table 1 Baseline demographic characteristics and clinical features of participants with treatment-resistant depression receiving TAU
with or without adjunctive VNS + TAU (two-sided t-test P-value for continuous data and asymptotic normal test P-value for categorical
data)
VNS + TAU (N=328)

TAU (N=271)

Mean or N

SD or %

Mean or N

SD or %

Age (years)

48.8

10.37

50.0

10.80

0.168

Number of female subjects

225

68.6

192

70.8

0.612

Number of white subjects

318

97.0

246

90.8

0.002

Age at initial onset of depression (years)

20.8

12.12

21.4

11.54

0.536

Age at initial diagnosis of depression (years)

29.0

10.90

29.7

11.67

0.451

Number of failed treatments for depression

8.0

3.04

7.4

2.93

0.014

Lifetime number of diagnosed depressive episode

15.1

24.34

11.7

24.56

0.090

Psychiatric hospitalizations within prior 5 years

2.8

4.63

1.5

2.87

0.001

Lifetime suicide attempts

2.0

4.35

1.2

2.32

0.004

History of electroconvulsive therapy

191

58.2

107

39.5

0.001

Moderate recurrent major depression

40

12.2

66

24.4

0.001

Severe recurrent major depression

133

40.5

85

31.4

0.025

Moderate single-episode major depression

12

3.7

29

10.7

0.001

Severe single-episode major depression

46

14.0

32

11.8

0.496

Bipolar I, currently moderately severe major depressive episode

19

5.8

18

6.6

0.795

Bipolar I, currently severe major depressive episode

46

14.0

10

3.7

0.001

Bipolar II, currently depressed

32

9.8

31

11.4

0.592

Montgomery–Åsberg Depression Rating Scale

33.2

7.67

29.5

6.40

0.001

Clinical Global Impressions-Severity

5.2

0.78

4.7

0.72

0.001

Quick Inventory of Depressive Symptomatology-Self Report

18.3

4.67

15.8

4.92

0.001

P-value

DSM-IV-TR primary diagnosis

Baseline scores

Abbreviations: TAU, treatment as usual; VNS, vagus nerve stumulation.
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1. In persons with TRD, does VNS + TAU differ from TAU
alone in regard to the onset of response (defined by at least
a 50% reduction in baseline MADRS) and cumulative
response rate over time?
In a similar data set, VNS + TAU demonstrated greater
cumulative first onset of antidepressant response.6 A similar
analysis was performed here to confirm if the trends are
maintained in this sample. Overall, 62.5% (205/328) of participants in the VNS + TAU arm had a first response during
the entire follow-up, compared to 39.9% (108/271) of participants in the TAU arm. The KM plot of time to first response
shows that the time to first response was significantly shorter
for VNS + TAU than for TAU alone (P0.01 for log-rank
test) (Figure 1) and the estimated cumulative probability for
the time to first response is higher for VNS + TAU participants compared to TAU participants over the majority of the
follow-up period (Table 2). Median time to the first response
was 18.1 months (Q1=6.9, Q3=49.1) for VNS + TAU participants compared to 49.1 months (Q1=12.3, Q3=not estimable) for TAU participants. HR for time to first response
for VNS + TAU compared to TAU was 2.0 (95% CI: 1.6,
2.5) meaning a statistically significantly larger chance for a
VNS + TAU participant to get a first response compared to
TAU participants at any given time during the follow-up.
2. In individuals who achieve a first response, does VNS +
TAU differ from TAU alone in regard to the duration of

the response (defined a priori as maintenance of at least
a 40% reduction from baseline MADRS)?
A total of 148 (148/205=72.2%) participants had a
first response in the first year in VNS + TAU arm and 69
(69/108=63.9%) participants had a first response in first
year in the TAU arm. Of the 148 in the VNS + TAU arm,
98 (98/148=66.2%) participants relapsed from their first
response during the study. Out of the 69 participants with
first response in first year in the TAU arm, 55 (55/69=79.7%)
participants relapsed from first response during the study.
KM plot of time to relapse from first response demonstrates
significantly longer time to relapse for the VNS + TAU
arm (P0.01 for log-rank test) (Figure 2). When response
occurred within the first 12 months of initiating treatment,
time to relapse took 1 year or longer for 47% of the responders in VNS + TAU, compared to 39% of the responders in
TAU (Table 2). Median time to relapse from first response
in first year was 10.1 months (Q1=4.2, Q3=31.5) for
VNS + TAU and 7.3 months (Q1=3.1, Q3=17.6) for TAU.
HR for time to relapse for VNS + TAU compared to TAU
was 0.6 (95% CI: 0.4, 0.9) indicating a significantly lower
probability for VNS + TAU participants to lose response
compared to TAU participants at any given time during
the follow-up.
3. In VNS + TAU group, is the time at which the first
response occurs related to the durability of that response?

1.0
VNS + TAU
TAU

0.9
0.8

Probability
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Participants who were available to respond
Time (months)
TAU
VNS + TAU

0

6
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42

48
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271
328
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242

159
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99
77
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40

67
39

56
30

40
24

Figure 1 A Kaplan–Meier plot demonstrates time to first response among 328 participants in the VNS + TAU group and 271 participants in the TAU group.
Notes: Time to first response was defined as the time from baseline to the first visit with a reduction in MADRS score of 50% compared to baseline. Median time to the
first response was 18.1 months (Q1=6.9, Q3=49.1) for VNS + TAU participants compared to 49.1 months (Q1=12.3, Q3= not estimable) for TAU participants.
Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; TAU, treatment as usual; VNS, vagus nerve stimulation.
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Table 2 Kaplan–Meier probability estimates with 95% CI
Probability of first response over time
3 months

6 months

9 months

12 months

0 (0, 0.03)
0.01 (0, 0.03)

0.10 (0.07, 0.15)
0.22 (0.17, 0.27)

0.19 (0.15, 0.24)
0.33 (0.28, 0.38)

0.24 (0.19, 0.30)
0.42 (0.36, 0.47)

Probability of retaining the first response (response durability) over time
TAU
VNS + TAU

0.75 (0.63, 0.84)
0.85 (0.78, 0.9)

0.58 (0.45, 0.69)
0.65 (0.57, 0.73)

0.41 (0.29, 0.53)
0.52 (0.43, 0.6)

0.39 (0.27, 0.51)
0.47 (0.38, 0.56)

Probability of second response over time following relapse from the first response
TAU
VNS + TAU

0
0.07 (0.04, 0.15)

0.13 (0.06, 0.27)
0.26 (0.18, 0.36)

0.27 (0.16, 0.43)
0.44 (0.35, 0.55)

0.32 (0.20, 0.48)
0.47 (0.37, 0.58)

Probability of retaining second response (response durability) over time
TAU
VNS + TAU

0.97 (0.79, 1)
0.98 (0.89, 1)

0.82 (0.63, 0.92)
0.89 (0.78, 0.95)

0.63 (0.42, 0.78)
0.73 (0.59, 0.82)

0.46 (0.27, 0.64)
0.66 (0.52, 0.77)

Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.

In VNS + TAU group, the probability of retaining the
first response beyond 1 year is higher in early responders
(those who first responded at 3 or 6 months visits) than
in late responders (those who first responded at 9 or
12 months) although the sample size is not sufficient to
make any definite conclusion (P≈1.00 for log-rank test)
(Figure 3). We conducted similar analysis putting early
responders (3 or 6 months) as one group and late responders
(9 or 12 months) as another group. Pattern was similar
(Figure S1) (P=0.06).

4. In each treatment group, does VNS + TAU differ from
TAU alone in regard to the onset of a second response for
participants that has relapsed from first response? How
does VNS + TAU differ from TAU in terms of retaining
a second response?
There is a substantial chance of a second response after
the first response in both the TAU and VNS + TAU groups
(Figure S2; Table 2). The two treatment arms do not differ
significantly in the timing or overall likelihood of having a
second response as measured from the time when the first
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Figure 2 A Kaplan–Meier plot for durability of the first response that occurred within the first year.
Notes: Duration of first response was defined as the time from first response to the first visit when reduction in MADRS score was 40% compared to baseline (ie, relapse).
Median time to relapse from first response in first year was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU and 7.3 months (Q1=3.1, Q3=17.6) for TAU.
Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; TAU, treatment as usual; VNS, vagus nerve stimulation.
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Figure 3 A Kaplan–Meier plot for durability of first response in the first year for VNS + TAU participants by visit.
Note: The trend in the probability of retaining the first response beyond 1 year was higher in the early responders (ie, those who first responded at 3 or 6 months after
VNS initiation) compared with the late responders (ie, those who first responded at 9 or 12 months after VNS initiation).
Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.

response was lost. Thus, VNS neither increases nor apparently decreases the chances of the second response. However,
more participants initially responded to VNS + TAU. Thus,
achieving a second response is presumably occurring in at
least some participants whose depression would be unlikely
to respond to TAU alone.
The durability of the second response when it occurs
with VNS + TAU may be more durable than the second
response to TAU alone (P=0.06) (Figure S3; Table 2). The
analysis is limited by sample sizes. However, it indicates
that VNS has no obvious negative effect in the durability of
the second response.

Discussion
In this nonrandomized comparative study of participants
with either bipolar depression (30%) or unipolar depression
with very substantial levels of treatment resistance, we found
that symptomatic response defined by the MADRS was
about twice as likely in those who received VNS + TAU
as compared to TAU alone at 1-year postimplant. For those
who responded, the duration of that benefit was significantly
longer for those who received VNS + TAU than for those
in TAU alone. At 12 months after the initial response, 47%

Neuropsychiatric Disease and Treatment 2019:15

of those who had responded to VNS + TAU still retained
their response, compared to 39% of responders to TAU.
Furthermore, there were suggestive (but not statistically
significant) indications that those who achieved an earlier
depression symptom benefit were more likely to sustain that
benefit for at least 1 year.
Results also revealed that in both VNS + TAU and TAU
groups, when a response was lost, a second response did
occur for a substantial percentage of participants within
12 months after losing the initial response. Approximately
half of the participants in the VNS + TAU group, as compared
to about 1/3 of those in the TAU, had their second response
within 12 months. There was no statistically significant difference between the two groups in the probability or timing
of onset of achieving a second response. When this second
response did occur, it may have been more durable for those
treated with VNS + TAU than for TAU alone – persisting
for at least 12 months for 66% in the VNS + TAU group vs
46% for TAU alone. However, these percentages are not
statistically different.
This is the first study to look at the long-term durability of benefit up to 4 years, defined here as response based
on 50% reduction in baseline MADRS score to declare the
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onset of response and a threshold of retaining at least a 40%
reduction compared to baseline to retain the response. As
expected from prior reports, the probability and timing of
first response were more likely to be sooner with adjunctive
VNS treatment than with TAU alone. In terms of long-term
durability, VNS + TAU participants are expected to retain
their response longer than TAU participants (HR=0.6, 95%
CI: 0.4, 0.9).6 Similar to prior reports, a substantial proportion (about 50%) of participants who achieved a response
maintained that benefit for at least a year after the response
began.9,13,20 In addition, while half of these participants lost
this initial response, half achieved a second response in
12 months. Furthermore, with adjunctive VNS, the second
response was retained in two out of three participants for an
additional 12 months.
The durability of response in this cohort was somewhat
lower than expected from the previous pilot studies and randomized controlled trials.8,21 Possible explanations include
the following: 1) these participants were treated under general
clinical conditions not managed by research staff and 2) the
sample contained 30% with bipolar depression whereas the
other samples generally included about 10%–15% of bipolar depressed participants. A greater waxing and waning of
symptoms would be expected from the bipolar sample. This
issue was examined in our sample and we found no difference in response between participants diagnosed with bipolar
depression vs unipolar depression (Figure S4). The present
data also indicate that VNS is not impairing participant’s
ability to achieve a second response following an initial
response and subsequent relapse.
Comparison of the durability of the first response in this
TRD sample is challenging due to sample size limitations
and to the fact that any comparison between these treatment
arms is contingent on a response having occurred. That is,
we are comparing only those who responded in each arm.
VNS + TAU produced more responders even though they
likely included more difficult-to-treat (poorer prognosis)
depressions that are at greater risk of relapse (ie, are not able
to sustain a benefit once it occurs). Despite this likely bias
against VNS + TAU in these two responder samples, the
HR of 0.6 (95% CI: 0.4, 0.9) reveals a significantly smaller
chance of loss of response for a VNS + TAU responder than
for a responder in TAU.
Another benchmark by which to evaluate the present
results is the Level 4 STAR-D participants all of whom had
failed on three prior well-delivered medication treatments.1
While the acute trial was only 12 weeks in the fourth step,
the remission rate was 15% and the response rate was not
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much greater. Of those who entered follow-up, most had
responded but had not achieved remission prior to entering
follow-up. Their relapse rate was over 80% over 12 months,
which is substantially greater than the roughly 45% 12-month
relapse rate for VNS + TAU participants and roughly 65%
relapse rate for TAU participants.

Limitations
This study has several limitations: the two groups were not
randomized, although majority of their clinical characteristics
were comparable. In fact, the higher rate of prior ECT treatment (58% in VNS + TAU compared to 40% in TAU arm)
and the higher proportion of severe recurrent major depression in VNS + TAU would suggest that the VNS + TAU
group was more severely ill. In addition, there was no control
for treatment. That is, we cannot conclude with certainty that
all the observed effects were exclusively related to adjunctive
VNS treatment. In this effectiveness trial, medications and
other treatments, such as TMS and ECT, could change for
the participants in both treatment arms though Conway et al
(2018) mentioned unpublished results that showed that there
were more medication changes in the TAU group. Thus, it is
unlikely that benefits seen for VNS + TAU patients were due
to other therapies.22 Furthermore, participants and clinicians
were knowledgeable about the care being given. However,
the off-site central raters collecting the MADRS were blind
to both treatment arm and overall clinical status. The participant population limits generalizability, though it is of course
reasonably representative of participants suffering from TRD.
Finally, in this 5-year longitudinal study, participant attrition
over time limits our ability to address with sufficient sample
sizes some of the questions posed. The primary reasons for
attrition did not fall in an identifiable category and hence was
collected in the database under category “Others”. The next
two significant reasons for attrition were consent withdrawal
and noncompliance.

Conclusion
Persons with severe TRD who are treated with adjunctive
VNS have a reasonable probability of achieving response
within the first year (42%). Of those responders, VNS +
TAU participants retain response longer compared to TAU
participants; close to 50% can expect to retain that benefit
over the subsequent 12 months. For those who lose that
benefit, the chances of a second response are on the order of
50% within the subsequent 12 months and when a second
response occurs, two-thirds in VNS + TAU and less than
half in TAU can expect to retain it for the subsequent year.

Neuropsychiatric Disease and Treatment 2019:15

Dovepress

Ethics statement

Neuropsychiatric Disease and Treatment downloaded from https://www.dovepress.com/ by 128.252.174.220 on 11-Jul-2019
For personal use only.

The TRD registry study was approved by the Western Institutional Review Board. A written informed consent was
obtained from all participants in the study in accordance with
the Declaration of Helsinki.

Data sharing statement
Data and results related to the TRD registry study that are
open access can be found at https://clinicaltrials.gov/ct2/
show/results/NCT00320372. Deidentified participant’s data
for the TRD registry study will not be shared.

Acknowledgments
The authors would like to thank the patients who participated
in the TRD registry study, as well as the principal investigators and study staff. The registry was sponsored by Cyberonics, Inc. (currently LivaNova, PLC), through contracts to
investigative sites. The authors appreciate the editorial
support of Karishma Manzur, PhD, employee of Lenimen
Consulting, Inc. ClinicalTrials.gov Identifier: NCT00320372.

Disclosure
Dr Kumar is an employee of LivaNova USA PLC. Dr Bunker
is a former employee and a current consultant of LivaNova
USA PLC. Mr Mordenti is an employee of LivaNova PLC.
Dr Aaronson has received consulting fees from Genomind,
LivaNova PLC, Alkermes PLC, and Neuronetics; research
support from Neuronetics; and speaking fees from Neurocrine Biosciences, Inc., Otsuka Pharmaceuticals Co., Ltd.,
and Sunovion Pharmaceuticals, Inc. Dr Conway has received
research support from Bristol–Myers Squibb, The Stanley
Medical Research Institute, the National Institute of Mental
Health, NeoSync, Inc., Cyberonics, Inc., Taylor Family Institute for Innovative Psychiatric Research, American Foundation for Suicide Prevention, Assurex Health, Inc., August
Busch IV Foundation, and The Foundation for Barnes‑Jewish
Hospital. He is currently serving as a research consultant for
LivaNova PLC. Dr Rothschild has received grant or research
support from Allergan PLC, Janssen, the National Institute of
Mental Health, Takeda, Eli Lilly and Company (medications
for a NIH-funded clinical trial), and Pfizer Inc. (medications
for a NIH-funded clinical trial), is a consultant to Alkermes,
GlaxoSmithKline, Sage Therapeutics, and Sanofi Aventis
LLC, and has received royalties for the Rothschild Scale for
Antidepressant Tachyphylaxis (RSAT)®; Clinical Manual
for the Diagnosis and Treatment of Psychotic Depression,
American Psychiatric Press, 2009; The Evidence-Based
Guide to Antipsychotic Medications, American Psychiatric

Neuropsychiatric Disease and Treatment 2019:15

Kumar et al

Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012; and
UpToDate®. Dr Rush has received consulting fees from Akili,
Brain Resource Inc., Compass Inc., Curbstone Consultant
LLC, Emmes Corp., Johnson and Johnson (Janssen), LivaNova, Mind Linc, Sunovion, Taj Medical; speaking fees
from LivaNova; and royalties from Guilford Press and the
University of Texas Southwestern Medical Center, Dallas,
TX (for the inventory of depressive symptoms and its derivatives). He is also named coinventor on two patents: US Patent
No 7,795,033: Methods to Predict the Outcome of Treatment
with Antidepressant Medication, Inventors: McMahon FJ,
Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and
US Patent No 7,906,283: Methods to Identify Patients at
Risk of Developing Adverse Events During Treatment with
Antidepressant Medication, Inventors: McMahon FJ, Laje G,
Manji H, Rush AJ, Paddock S. The authors report no other
conflicts of interest in this work.

References

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term
outcomes in depressed outpatients requiring one or several treatment
steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
2. Thase ME, Rush AJ. When at first you don’t succeed: sequential
strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;
58(Suppl 13):23–29.
3. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for
consensus definitions of terms in major depressive disorder, remission,
recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):
851–855.
4. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task
Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841–1853.
5. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for
treatment-resistant depression: acute and chronic effects. Brain Stimul.
2013;6(4):631–640.
6. Aaronson ST, Sears P, Ruvuna F, et al. A 5-year observational study
of patients with treatment-resistant depression treated with vagus nerve
stimulation or treatment as usual: comparison of response, remission,
and suicidality. Am J Psychiatry. 2017;174(7):640–648.
7. AHRQ. Technology Assessment Program: Definition of TreatmentResistant Depression in the Medicare Population. Project ID:
PSYT0816. Agency for Healthcare Research and Quality. US Department of Health and Human Services. 2018. Available from: https://
www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/
id105TA.pdf. Accessed April 18, 2018.
8. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of
vagus nerve stimulation in treatment-resistant depression: a naturalistic
study. Biol Psychiatry. 2005;58(5):355–363.
9. Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, Rush AJ.
A patient-level meta-analysis of studies evaluating vagus nerve stimulation
therapy for treatment-resistant depression. Med Devices. 2013;6:17–35.
10. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation
(VNS) for treatment-resistant depressions: a multicenter study. Biol
Psychiatry. 2000;47(4):276–286.
11. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation
for treatment-resistant depression: a randomized, controlled acute phase
trial. Biol Psychiatry. 2005;58(5):347–354.

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

465

Neuropsychiatric Disease and Treatment downloaded from https://www.dovepress.com/ by 128.252.174.220 on 11-Jul-2019
For personal use only.

Kumar et al
12. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of
vagus nerve stimulation with treatment as usual for treatment-resistant
depression. Biol Psychiatry. 2005;58(5):364–373.
13. Sackeim HA, Brannan SK, Rush AJ, George MS, Marangell LB, Allen J.
Durability of antidepressant response to vagus nerve stimulation (VNS).
Int J Neuropsychopharmacol. 2007;10(6):817–826.
14. Montgomery SA, Asberg M. A new depression scale designed to be
sensitive to change. Br J Psychiatry. 1979;134:382–389.
15. Olin B, Jayewardene AK, Bunker M, Moreno F. Mortality and suicide
risk in treatment-resistant depression: an observational study of the
long-term impact of intervention. PLoS One. 2012;7(10):e48002.
16. Trivedi MH, Rush AJ, Ibrahim HM, et al. The inventory of depressive
symptomatology, clinician rating (IDS-C) and self-report (IDS-SR),
and the quick inventory of depressive symptomatology, clinician
rating (QIDS-C) and self-report (QIDS-SR) in public sector patients
with mood disorders: a psychometric evaluation. Psychol Med. 2004;
34(1):73–82.
17. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item quick inventory
of depressive symptomatology (QIDS), clinician rating (QIDS-C),
and self-report (QIDS-SR): a psychometric evaluation in patients with
chronic major depression. Biol Psychiatry. 2003;54(5):573–583.

466

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Dovepress
18. Guy W. ECDEU Assessment Manual for Psychopharmacology.
Rockville, MD: US Department of Health, Education, and Welfare;
1976.
19. Zimmerman M, Posternak MA, Chelminski I. Defining remission on
the Montgomery-Asberg depression rating scale. J Clin Psychiatry.
2004;65(2):163–168.
20. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus
nerve stimulation (VNS) for treatment of major depressive episodes.
J Clin Psychiatry. 2005;66(9):1097–1104.
21. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol
Psychiatry. 2002;51(4):280–287.
22. Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ.
Chronic vagus nerve stimulation significantly improves quality of
life in treatment-resistant major depression. J Clin Psychiatry. 2018;
79(5):52–59.

Neuropsychiatric Disease and Treatment 2019:15

Dovepress

Kumar et al

3UREDELOLW\













RUPRQWKV
RUPRQWKV

























7LPHDIWHUILUVWUHVSRQVH PRQWKV
Figure S1 A Kaplan–Meier plot for durability of first response in the first year for VNS + TAU participants by early and late responder.
Note: The trend in the probability of retaining the first response beyond 1 year was higher in the early responder group (ie, first response at 3 or 6 months after VNS
initiation) compared with the late responder group (ie, first response at 9 or 12 months after VNS initiation).
Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.
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Figure S2 A Kaplan–Meier plot shows the chance of a second response after relapse following the first response within the first year in both VNS + TAU and TAU.
Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.
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Figure S3 A Kaplan–Meier plot demonstrates that the second response may be more durable with VNS + TAU versus TAU.
Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.
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7LPHDIWHUILUVWUHVSRQVH PRQWKV
Figure S4 A Kaplan–Meier plot demonstrates that there was no difference in durability of the response in either treatment group based on the polarity of the depression.
Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.
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